ProstaScint and its role in the diagnosis of prostate cancer.
Cancer of the prostate is the most common cancer in males accounting for 33% of newly diagnosed cases. It is the second leading cause of cancer death in American males. The prevalence of prostate cancer increases most rapidly with age and the incidence (unlike other cancers) continues to rise with advancing age. Death due to this cancer is almost invariably the result of failure to control metastatic disease. In addition, several studies have demonstrated that over 30% of patients will experience biochemical recurrence after surgery with long-term (more than 10 years) follow-up. Information regarding the location of the cancer is critical to the success of initial therapy when deciding between local versus systemic treatment options in the newly diagnosed patient. For patients who have already undergone definitive treatment, the localization of recurrent tumor, evidenced by an elevation of prostate-specific antigen, is difficult unless the tumor burden is large enough to be detected on conventional radiographic studies or digital rectal examination and prostatic fossa biopsy. ProstaScint is a diagnostic tool used to detect metastatic prostate cancer in lymph nodes or other sites. This article provides an overview on the uses of ProstaScint in the assessment of patients with recurrent or metastatic prostate cancer.
Mohammed
Aza A
AA
King George Hospital, Department of Urology, Essex, UK. aza_bamerny@yahoo.com
Shergill
Iqbal S
IS
Vandal
Mohammad T
MT
Gujral
Sandeep S
SS
D000818:Animals; D000911:Antibodies, Monoclonal; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000276:immunology*
D000911:Antibodies, Monoclonal; C101315:Capromab Pendetide